Literature DB >> 26819307

The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.

Shoko Nishiyama1, Nandadeva Lokugamage1, Tetsuro Ikegami2.   

Abstract

UNLABELLED: Rift Valley fever (RVF) is endemic to Africa, and the mosquito-borne disease is characterized by "abortion storms" in ruminants and by hemorrhagic fever, encephalitis, and blindness in humans. Rift Valley fever virus (RVFV; family Bunyaviridae, genus Phlebovirus) has a tripartite negative-stranded RNA genome (L, M, and S segments). A live-attenuated vaccine for RVF, the MP-12 vaccine, is conditionally licensed for veterinary use in the United States. MP-12 is fully attenuated by the combination of the partially attenuated L, M, and S segments. Temperature sensitivity (ts) limits viral replication at a restrictive temperature and may be involved with viral attenuation. In this study, we aimed to characterize the ts mutations for MP-12. The MP-12 vaccine showed restricted replication at 38°C and replication shutoff (100-fold or greater reduction in virus titer compared to that at 37°C) at 39°C in Vero and MRC-5 cells. Using rZH501 reassortants with either the MP-12 L, M, or S segment, we found that all three segments encode a temperature-sensitive phenotype. However, the ts phenotype of the S segment was weaker than that of the M or L segment. We identified Gn-Y259H, Gc-R1182G, L-V172A, and L-M1244I as major ts mutations for MP-12. The ts mutations in the L segment decreased viral RNA synthesis, while those in the M segment delayed progeny production from infected cells. We also found that a lack of NSs and/or 78kD/NSm protein expression minimally affected the ts phenotype. Our study revealed that MP-12 is a unique vaccine carrying ts mutations in the L, M, and S segments. IMPORTANCE: Rift Valley fever (RVF) is a mosquito-borne viral disease endemic to Africa, characterized by high rates of abortion in ruminants and severe diseases in humans. Vaccination is important to prevent the spread of disease, and a live-attenuated MP-12 vaccine is currently the only vaccine with a conditional license in the United States. This study determined the temperature sensitivity (ts) of MP-12 vaccine to understand virologic characteristics. Our study revealed that MP-12 vaccine contains ts mutations independently in the L, M, and S segments and that MP-12 displays a restrictive replication at 38°C.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26819307      PMCID: PMC4794659          DOI: 10.1128/JVI.02241-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Jing Wu; Roberta Pugh; Pooja Kanani; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

2.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  A procedure for the prediction of temperature-sensitive mutants of a globular protein based solely on the amino acid sequence.

Authors:  R Varadarajan; H A Nagarajaram; C Ramakrishnan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

4.  Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs.

Authors:  M Bouloy; C Janzen; P Vialat; H Khun; J Pavlovic; M Huerre; O Haller
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts antiapoptotic function.

Authors:  Kaori Terasaki; Sungyong Won; Shinji Makino
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

6.  Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets.

Authors:  Amy L Hartman; Diana S Powell; Laura M Bethel; Amy L Caroline; Richard J Schmid; Tim Oury; Douglas S Reed
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

7.  Body temperature of C57BL/6J mice with age.

Authors:  M Talan
Journal:  Exp Gerontol       Date:  1984       Impact factor: 4.032

8.  Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.

Authors:  E K Subbarao; E J Park; C M Lawson; A Y Chen; B R Murphy
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome.

Authors:  Gema Lorenzo; Miguel Rodríguez-Pulido; Elena López-Gil; Francisco Sobrino; Belén Borrego; Margarita Sáiz; Alejandro Brun
Journal:  Antiviral Res       Date:  2014-06-25       Impact factor: 5.970

Review 10.  The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment.

Authors:  Amy C Shurtleff; Nicole Garza; Matthew Lackemeyer; Ricardo Carrion; Anthony Griffiths; Jean Patterson; Samuel S Edwin; Sina Bavari
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more
  8 in total

Review 1.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

2.  Attenuation of pathogenic Rift Valley fever virus strain through the chimeric S-segment encoding sandfly fever phlebovirus NSs or a dominant-negative PKR.

Authors:  Shoko Nishiyama; Olga A L Slack; Nandadeva Lokugamage; Terence E Hill; Terry L Juelich; Lihong Zhang; Jennifer K Smith; David Perez; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Virulence       Date:  2016-06-01       Impact factor: 5.882

3.  Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain.

Authors:  Hoai J Ly; Shoko Nishiyama; Nandadeva Lokugamage; Jennifer K Smith; Lihong Zhang; David Perez; Terry L Juelich; Alexander N Freiberg; Tetsuro Ikegami
Journal:  Vaccine       Date:  2017-10-20       Impact factor: 3.641

4.  Mutational Analysis of the Rift Valley Fever Virus Glycoprotein Precursor Proteins for Gn Protein Expression.

Authors:  Inaia Phoenix; Nandadeva Lokugamage; Shoko Nishiyama; Tetsuro Ikegami
Journal:  Viruses       Date:  2016-05-24       Impact factor: 5.048

5.  Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells.

Authors:  Nandadeva Lokugamage; Tetsuro Ikegami
Journal:  NPJ Vaccines       Date:  2017-07-17       Impact factor: 7.344

6.  Development of a Simian RNA Polymerase I Promoter-Driven Reverse Genetics for the Rescue of Recombinant Rift Valley Fever Virus from Vero Cells.

Authors:  Tetsuro Ikegami
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

7.  Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models.

Authors:  Tetsuro Ikegami; Eduardo Jurado-Cobena; Cigdem Alkan; Jennifer K Smith; Lihong Zhang; Birte Kalveram; Terry L Juelich; Allen T Esterly; Jahnavi R Bhaskar; Saravanan Thangamani; Alexander N Freiberg
Journal:  NPJ Vaccines       Date:  2022-09-21       Impact factor: 9.399

8.  Replication capacity and adaptability of a severe fever with thrombocytopenia syndrome virus at different temperatures.

Authors:  Yan Feng; Changping Xu; Cixiu Li; Junfen Lin; Zhongfa Wang; Yanjun Zhang; Jianmin Jiang; Yiyu Lu
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.